Leprosy continues to be a challenge to health worldwide, with about 250 000 new cases
being detected every year. Despite widespread implementation of effective multidrug …

Our improved understanding of how innate immune responses can be initiated and how
they can shape adaptive B‐and T‐cell responses is having a significant impact on vaccine …

Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a
component of Gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and …

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) rapidly infects
humans and animals which make coronavirus disease 2019 (COVID-19) a grievous …

Mycobacterium leprae is the causative agent responsible for the chronic disease known as
leprosy. This condition is characterized by dermal involvement, often leading to peripheral …

Leprosy is a curable disease, having been eliminated from many countries, including India.
This has been possible due to the wide availability of effective and safe drugs. Treatment of …

Glucopyranosyl lipid adjuvant‐stable emulsion (GLA‐SE) is a synthetic adjuvant TLR4
agonist that promotes potent poly‐functional TH1 responses. Different TLR4 agonists may …

Abstract According to the World Health Organization (WHO), tuberculosis (TB) is the leading
cause of death triggered by a single infectious agent, worldwide. Bacillus Calmette-Guerin …

The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable
emulsion (GLA-SE) promotes strong TH1 and balanced IgG1/IgG2 responses to protein …

Prevalence rates for leprosy have declined sharply over the past 20 y, with this decline
generally attributed to the WHO multi-drug therapy (MDT) campaign to provide free-of …